Pharmacologic Treatment of Osteogenesis Imperfecta: New Agents and their Potential Implications for Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 479

lethal mutations align with collagen binding sites for integrins
and proteoglycans. Hum Mutat 2007;28(3):209-21.

in children with osteogenesis imperfecta: histomorphometric
study. J Bone Miner Res 2011;26(9):2245-51.
[33] Martin E, BrintzenhofeSzoc K, Shapiro JR. Vitamin D deficiency in
osteogenesis imperfecta. Poster presentation. ASBMR Conference
on Contemporary Diagnosis and Treatment of Vitamin D-related
Disorders: ASBMR; 2006 December 4-5, 2006.
[34] Shapiro JR., McMahon E., Hollis B. Recommendations regarding
vitamin D intake in osteogenesis imperfecta. 2012 Apr 30.

[13] Martin E, Shapiro JR. Osteogenesis imperfecta: epidemiology

and pathophysiology. Curr Osteoporos Rep 2007;5(3):91-7.

[14] Holick MF. Vitamin D deiciency. N Engl J Med 2007;357(3):266-81.

[15] Bowden SA, Robinson RF, Carr R, Mahan JD. Prevalence of vita-

min D deiciency and insuficiency in children with osteopenia
or osteoporosis referred to a pediatric metabolic bone clinic.
Pediatrics 2008;121(6):e1585-90. [35] Chagas CE, Roque JP, Santarosa Emo Peters B, Lazaretti-Castro M,

Martini LA. Do patients with osteogenesis imperfecta need indi-
vidualized nutritional support? Nutrition 2012;28(2):138-42.

[16] Orwoll E, Nielson CM, Marshall LM, Lambert L, Holton KF,

Hoffman AR, et al. Vitamin D deiciency in older men. J Clin
Endocrinol Metab 2009;94(4):1214-22. [36] Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium

supplements with or without vitamin D and risk of cardiovas-
cular events: reanalysis of the women's health initiative limited
access dataset and meta-analysis. BMJ 2011;342:d2040.

[17] Merewood A, Mehta SD, Grossman X, Chen TC, Mathieu J,

Holick MF, et al. Vitamin D status among 4-month-old infants
in New England: a prospective cohort study. J Hum Lact 2012;
28(2):159-66. [37] Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA,

Reginster JY, et al. Effect of parathyroid hormone (1-34) on frac-
tures and bone mineral density in postmenopausal women with
osteoporosis. N Engl J Med 2001;344(19):1434-41.

[18] Arabi A, Baddoura R, Awada H, Salamoun M, Ayoub G,

El-Hajj Fuleihan G. Hypovitaminosis D osteopathy: is it medi-
ated through PTH, lean mass, or is it a direct effect? Bone 2006;
39(2):268-75. [38] Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid

hormone in the treatment of osteoporosis. Rev Endocr Metab
Disord 2006;7(1-2):113-21.

[19] Holick MF. Optimal vitamin D status for the prevention and

treatment of osteoporosis. Drugs Aging 2007;24(12):1017-29.

[20] Ginde AA, Wolfe P, Camargo Jr CA, Schwartz RS. Deining vita-

min D status by secondary hyperparathyroidism in the U.S.
population. J Endocrinol Invest 2012;35(1):42-8.

[39] Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R,

Zanchetta JR, et al. Effect of recombinant human parathyroid
hormone (1-84) on vertebral fracture and bone mineral density
in postmenopausal women with osteoporosis: a randomized
trial. Ann Intern Med 2007;146(5):326-39.

[21] Peacock M, Liu G, Carey M, McClintock R, Ambrosius W, Hui S,

et al. Effect of calcium or 25OH vitamin D3 dietary supplemen-
tation on bone loss at the hip in men and women over the age of
60. J Clin Endocrinol Metab 2000;85(9):3011-9.

[40] Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P. Effects

of parathyroid hormone alone or in combination with antire-
sorptive therapy on bone mineral density and fracture risk - a
meta-analysis. Osteoporos Int 2007;18(1):45-57.

[22] Edouard T, Husseini A, Glorieux FH, Rauch F. Serum

24,25-dihydroxyvitamin D concentrations in osteogenesis
imperfecta: relationship to bone parameters. J Clin Endocrinol
Metab 2012;97(4):1243-9.

[41] Misof BM, Paschalis EP, Blouin S, Fratzl-Zelman N, Klaushofer K,

Roschger P. Effects of 1 year of daily teriparatide treatment on ilia-
cal bone mineralization density distribution (BMDD) in postmeno-
pausal osteoporotic women previously treated with alendronate or
risedronate. J Bone Miner Res 2010;25(11):2297-303.

[23] Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B.

Positive association between 25-hydroxy vitamin D levels and
bone mineral density: a population-based study of younger and
older adults. Am J Med 2004;116(9):634-9. [42] Cusano NE, Costa AG, Silva BC, Bilezikian JP. Therapy of osteo-

porosis in men with teriparatide. J Osteoporos 2011;2011:463675. [24] Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis

CE, et al. Calcium plus vitamin D supplementation and the risk
of fractures. N Engl J Med 2006;354(7):669-83.

[43] Ejersted C, Andreassen TT, Hauge EM, Melsen F,

Oxlund H. Parathyroid hormone (1-34) increases vertebral
bone mass, compressive strength, and quality in old rats. Bone
1995;17(6):507-11.

[25] Ensrud KE, Taylor BC, Paudel ML, Cauley JA, Cawthon PM,

Cummings SR, et al. Serum 25-hydroxyvitamin D levels and
rate of hip bone loss in older men. J Clin Endocrinol Metab
2009;94(8):2773-80.

[44] Arita S, Ikeda S, Sakai A, Okimoto N, Akahoshi S, Nagashima M,

et al. Human parathyroid hormone (1-34) increases mass and
structure of the cortical shell, with resultant increase in lumbar
bone strength, in ovariectomized rats. J Bone Miner Metab 2004;
22(6):530-40.

[26] Cauley JA, Lacroix AZ, Wu L, Horwitz M, Danielson ME, Bauer

DC, et al. Serum 25-hydroxyvitamin D concentrations and risk
for hip fractures. Ann Intern Med 2008;149(4):242-50.

[27] Holick MF. Vitamin D: the other steroid hormone for muscle

function and strength. Menopause 2009;16(6):1077-8.

[45] Locklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the bipha-

sic responses of bone to intermittent and continuously adminis-
tered parathyroid hormone. J Cell Biochem 2003;89(1):180-90. [28] Daly RM, Bass S, Nowson C. Long-term effects of calcium-vita-

min-D3-fortiied milk on bone geometry and strength in older
men. Bone 2006;39(4):946-53.

[46] Aslan D, Andersen MD, Gede LB, de Franca TK, Jorgensen SR,

Schwarz P, et al. Mechanisms for the bone anabolic effect of para-
thyroid hormone treatment in humans. Scand J Clin Lab Invest
2012;72(1):14-22.

[29] Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM,

Hanley DA, Heaney RP, et al. Evaluation, treatment, and
prevention of vitamin D deiciency: an endocrine soci-
ety clinical practice guideline. J Clin Endocrinol Metab
2011;96(7):1911-30.

[47] Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-

Perez A, et al. The effect of teriparatide [human parathyroid
hormone (1-34)] therapy on bone density in men with osteopo-
rosis. J Bone Miner Res 2003;18(1):9-17. [30] Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton

SK, et al. The 2011 report on dietary reference intakes for cal-
cium and vitamin D from the institute of medicine: what clini-
cians need to know. J Clin Endocrinol Metab 2011;96(1):53-8.

[48] Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A,

Dalsky GP, et al. Teriparatide effects on vertebral fractures and
bone mineral density in men with osteoporosis: treatment and
discontinuation of therapy. Osteoporos Int 2005;16(5):510-6. [31] Edouard T, Glorieux FH, Rauch F. Predictors and correlates of

vitamin D status in children and adolescents with osteogenesis
imperfecta. J Clin Endocrinol Metab 2011;96(10):3193-8.

[49] Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A,

et al. Sclerostin is a novel secreted osteoclast-derived bone mor-
phogenetic protein antagonist with unique ligand speciicity.
J Biol Chem 2003;278(26):24113-24117.

[32] Edouard T, Glorieux FH, Rauch F. Relationship between vita-

min D status and bone mineralization, mass, and metabolism